The White House has withdrawn Heidi Overton’s nomination to lead the US Food and Drug Administration, hours before a Senate committee vote that had been set for Wednesday. The Senate Health, Education, Labor and Pensions Committee was due to vote on 18 November on whether to send her name to the full Senate for confirmation. Officials said the administration pulled the nomination because it did not have the votes.
Overton, a White House health adviser, had come under attack from both parties. Senators questioned her record on vaccines, pesticides, food policy, the abortion pill mifepristone and fruit-flavoured vapes. Calley Means, who recently left his job as one of Health Secretary Robert F. Kennedy Jr’s top advisers, ran a public campaign against her and said she opposed Kennedy’s goals on pesticides, food policy, vaccines and psychedelic treatments.
Republican Senator Bill Cassidy of Louisiana, who chairs the Senate HELP committee, criticised Overton for helping craft President Donald Trump’s executive order proposing an overhaul of childhood vaccinations. Maine Republican Susan Collins raised concerns about the FDA’s authorisation of fruit-flavoured vapes earlier this year, and Alaska’s Lisa Murkowski raised concerns about the agency’s approach to mifepristone. Democratic Senator Ed Markey of Massachusetts said he would vote against her and urged colleagues to do the same. With support thinning, Republicans discussed Kansas Senator Roger Marshall as a possible replacement, Semafor reported.
The agency is left without a permanent leader
The withdrawal leaves the FDA without a permanent commissioner. Kyle Diamantas, an attorney who previously ran the agency’s food centre, is leading the FDA on a temporary basis and plans to leave by the end of the year. Former commissioner Marty Makary resigned in May after 13 months in the job. The agency regulates products that account for roughly a fifth of consumer spending in the United States, and the last round of political appointments placed vaccine sceptics in several top health posts.
For readers who follow US public health, the practical effect is a longer period of uncertainty. The United States lost its measles elimination status this year after 26 years, and the FDA is the agency that decides which vaccines and medicines reach the market. A long gap at the top can slow those decisions.
Overton is a deputy assistant to the president for domestic policy, focused on health issues. She is a medical doctor, holds a doctorate in clinical investigation from Johns Hopkins University, worked at the America First Policy Institute and was a White House fellow in the first Trump administration. Fierce Pharma reported that analysts at Citi called the withdrawal a modest negative for biopharma sentiment, but not a material near-term change to the regulatory environment.
The administration has now failed to fill several top health posts, including two surgeon general nominations and one for director of the Centers for Disease Control and Prevention. The Guardian reported that the White House may struggle to advance a nominee before Democrats take control of the Senate in January.
Who runs the FDA while the post is vacant? Kyle Diamantas, a career attorney who led the agency’s food centre, is the acting commissioner, and he has said he plans to leave by the end of the year.



